Evidence map›Paper›PMID 38224775›Full record

ArticleThe ocular surface2024

The Yin and Yang of non-immune and immune responses in meibomian gland dysfunction.

Cole J Beatty, Raul E Ruiz-Lozano, Manuel E Quiroga-Garza, Victor L Perez, James V Jester, Daniel R Saban

Open access · greenAbstract read
In one paragraph

Article in The ocular surface, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Cole J BeattyDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, USA; Duke Eye Center, Duke University School of Medicine, Foster Center for Ocular Immunology at Duke Eye Center, Durham, NC, USA.
Raul E Ruiz-LozanoDuke Eye Center, Duke University School of Medicine, Foster Center for Ocular Immunology at Duke Eye Center, Durham, NC, USA.
Manuel E Quiroga-GarzaDuke Eye Center, Duke University School of Medicine, Foster Center for Ocular Immunology at Duke Eye Center, Durham, NC, USA.
Victor L PerezDuke Eye Center, Duke University School of Medicine, Foster Center for Ocular Immunology at Duke Eye Center, Durham, NC, USA. Electronic address: vperez4@med.miami.edu.
James V JesterDepartment of Ophthalmology and Biomedical Engineering, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA, USA. Electronic address: JJester@hs.uci.edu.
Daniel R SabanDepartment of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, USA; Duke Eye Center, Duke University School of Medicine, Foster Center for Ocular Immunology at Duke Eye Center, Durham, NC, USA. Electronic address: daniel.saban@duke.edu.
Duke University · USUniversity of California, Irvine · US

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Goldis Malek · 1985 to 2026
$19.3M
Defining the Immune Cell Roles in Meibomian Gland Dysfunction in the Context of Ocular Surface Immune DiseasesR01EY021798 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI SABAN, DANIEL RAPHAEL · 2012 to 2025
$5.3M
Immune Mechanisms in Ocular Graft versus Host DiseaseR01EY024484 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LEVY, ROBERT BENJAMIN, PEREZ, VICTOR L · 2014 to 2025
$5.1M
Age-Related Meibomian Gland DysfunctionR01EY021510 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI James V Jester · 2011 to 2026
$4.8M
Basic Immunology Training ProgramT32AI052077 · NIAID · DUKE UNIVERSITY · PI KRANGEL, MICHAEL S · 2002 to 2024
$4.2M
NEI UCI Center Core Grant for Vision ResearchP30EY034070 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Vladimir Jivkov Kefalov · 2022 to 2026
$3.7M
NEI NIH HHS P30 EY005722NEI NIH HHS P30 EY034070NEI NIH HHS R01 EY021510NEI NIH HHS R01 EY021798NEI NIH HHS R01 EY024484NIAID NIH HHS T32 AI052077
6 · The paper itself

Abstract

Meibomian gland dysfunction (MGD) is a leading cause of dry eye disease and one of the most common ophthalmic conditions encountered in eye clinics worldwide. These holocrine glands are situated in the eyelid, where they produce specialized lipids, or meibum, needed to lubricate the eye surface and slow tear film evaporation - functions which are critical to preserving high-resolution vision. MGD results in tear instability, rapid tear evaporation, changes in local microflora, and dry eye disease, amongst other pathological entities. While studies identifying the mechanisms of MGD have generally focused on gland obstruction, we now know that age is a major risk factor for MGD that is associated with abnormal cell differentiation and renewal. It is also now appreciated that immune-inflammatory disorders, such as certain autoimmune diseases and atopy, may trigger MGD, as demonstrated through a T cell-driven neutrophil response. Here, we independently discuss the underlying roles of gland and immune related factors in MGD, as well as the integration of these two distinct mechanisms into a unified perspective that may aid future studies. From this unique standpoint, we propose a revised model in which glandular dysfunction and immunopathogenic pathways are not primary versus secondary contributors in MGD, but are fluid, interactive, and dynamic, which we likened to the Yin and Yang of MGD.

Indexed as

Meibomian Gland DysfunctionMeibomian GlandsTearsDry Eye SyndromesHumans

Identifiers

PMID38224775
PMCPMC11881750
OpenAlexW4390859772

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.